Xenon Pharmaceuticals Inc (STU:XP0)
€ 38.4 -0.2 (-0.52%) Market Cap: 2.90 Bil Enterprise Value: 2.27 Bil PE Ratio: 0 PB Ratio: 3.56 GF Score: 47/100

Xenon Pharmaceuticals Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript

May 03, 2022 / 03:30PM GMT
Release Date Price: €26.8
Unidentified Participant

Xenon Pharmaceuticals, presented by Ian Mortimer, President and CEO.

Ian Mortimer
Xenon Pharmaceuticals Inc, - President & CEO

Great, thanks for the introduction. And thanks to Bloom Burton for hosting us today. So if we look back over the last 12 months when we gave this presentation virtually a year ago, a huge massive transformation at Xenon. We had really compelling data in our lead program XEN1101 last fall, that allowed us to raise large amounts of capital. And now we're in a position to start our Phase 3 program later this year.

So I'm going to focus, although we have a pipeline of programs, I'm going to focus the presentation today on our XEN1101 program.

We are a public company listed on NASDAQ, so I will make some forward-looking statements, and I encourage you to look at our risk factors filed with the SEC and on SEDAR. So for those of you that are new to the Xenon story, we're a neurology-focused company, deep expertise in epilepsy, and a growing interest in depression.

And we actually had an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot